ChromaDex shares results of high dose Niagen and mild improvements in PD

“ChromaDex shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside supplementation on individuals with Parkinson’s disease. This study was part of the ChromaDex External Research Program CERP, which donated ChromaDex’s patented NR ingredient, Niagen ,the most efficient and high quality NAD+ precursor, for the advancement of this research. In a pioneering development for PD treatment, this landmark phase I randomized, double-blind clinical study reported in the peer-reviewed journal Nature Communications by a team of scientists led by Prof. Charalampos Tzoulis, Haukeland University Hospital and University of Bergen in Norway, demonstrated that supplementing individuals with PD with high-dose Niagen NR was short-term safe, greatly increased whole blood NAD+ levels, augmented the NAD+ metabolome, and was associated with a significant clinical improvement. These results build upon previous research led by Dr. Tzoulis and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research. PD is a common neurodegenerative disorder largely characterized by progressive impairments in motor function, including tremors, stiffness, slow movement, and poor balance, as well as in non-motor functions, such as abnormal sleep patterns, gastrointestinal dysfunction, and cognitive impairment, or dementia. Current treatment options are limited, and there is a pressing need for innovative approaches to manage the effects of this debilitating neurodegenerative disorder,” said the company in a statement.